University of New South Wales (UNSW) - Liverpool Hospital
Welcome,         Profile    Billing    Logout  
 0 Trials 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Davison, Scott
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( )

Recruiting
3
1000
Europe, Canada, US, RoW
IVA337, Lanifibranor, Placebo
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
09/25
09/26
YH001, NCT05212922: A Study to Evaluate in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC

Withdrawn
2
80
Europe, RoW
YH001 + Toripalimab
Eucure (Beijing) Biopharma Co., Ltd
HCC, NSCLC Stage IIIB, NSCLC Stage IV
12/24
03/25
IMPACT, NCT05989711: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH) ( Trial)

Active, not recruiting
2
190
US, RoW
Pemvidutide, Placebo
Altimmune, Inc.
Non-Alcoholic Steatohepatitis (NASH)
02/25
09/25

Download Options